Charles Schwab Investment Management Inc. Has $9.19 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 10.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,252,655 shares of the company’s stock after acquiring an additional 118,379 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Vir Biotechnology were worth $9,194,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. SBI Securities Co. Ltd. acquired a new stake in Vir Biotechnology during the 4th quarter worth about $60,000. Alta Partners Management Company L.P. acquired a new stake in Vir Biotechnology during the 4th quarter worth about $3,593,000. New York State Common Retirement Fund boosted its position in Vir Biotechnology by 163.8% during the 4th quarter. New York State Common Retirement Fund now owns 64,906 shares of the company’s stock worth $476,000 after acquiring an additional 40,300 shares during the period. CIBC Asset Management Inc acquired a new stake in Vir Biotechnology during the 4th quarter worth about $74,000. Finally, Principal Financial Group Inc. boosted its position in Vir Biotechnology by 3.7% during the 4th quarter. Principal Financial Group Inc. now owns 447,313 shares of the company’s stock worth $3,283,000 after acquiring an additional 15,902 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $6.93 on Friday. The stock’s 50 day simple moving average is $9.15 and its 200 day simple moving average is $8.39. Vir Biotechnology, Inc. has a twelve month low of $6.56 and a twelve month high of $14.45. The company has a market capitalization of $950.40 million, a price-to-earnings ratio of -1.77 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Barclays raised their price target on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Leerink Partners raised their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. The trade was a 0.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,859 shares of company stock valued at $326,458. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).